Dyne Therapeutics Inc (NAS:DYN)
$ 31.13 1.9 (6.5%) Market Cap: 3.17 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 4.49 GF Score: 42/100

Dyne Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 04, 2023 / 02:10PM GMT
Release Date Price: $9.5 (-14.03%)
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst

Good morning and welcome to day two of Guggenheim's Genomic Medicines and Rare Disease Conference. This is our fifth iteration. My name is Debjit, and I'm one of the therapeutic analysts at Guggenheim; my privilege to host Wildon Farwell, CMO; and Jonathan McNeill, SVP of Business Development from Dyne Therapeutics. I'm not sure if Amy is on the call as well, but if Amy is on, Amy Reilly, Head of Corporate Communications and IR is on as well.

Questions & Answers

Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst

Given the limited time, let's get straight to it on the thoughts on the FORCE platform and how the technology differentiates itself versus non-specific approaches in neuromuscular diseases?

Jonathan McNeill
Dyne Therapeutics, Inc. - SVP, Business Development

Yeah, thanks Debjit, thanks for the opportunity to join you today. Before we start, I just want to remind everyone that we'll be making forward-looking statements, so please

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot